Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b dose-ranging study of oral TAK-279 in moderate to severe active Crohn's disease
MOH_2025-09-13_014339Phase 2Recruiting
- Sponsor
- Takeda
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of zasocitinib in Crohn's disease (4 arms), sponsored by Takeda. Primary endpoint: Reduction in intestinal inflammation and ulceration at Week 12. Started Aug 2025; status: recruiting.
02
Drugs
zasocitinib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on MOH_2025-09-13_014339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-09-13_014339.